Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms

Daniel H. Lachance, Dagmar Oette, S. Clifford Schold, Mark Brown, Joanne Kurtzberg, Michael L. Graham, Robert Tien, Gary Felsberg, O. Michael Colvin, Albert Moghrabi, Iley Browning, Beverly Hockenberger, Elizabeth Stewart, Lee Ferrell, Tracy Kerby, Margaret Duncan‐Brown, Barry Golembe, Herb Fuchs, Ruth Fredericks, Frances Ann HayesAbbe Sue Rubin, Darell D. Bigner, Henry S. Friedman

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2). © 1995 Wi1ey‐Liss Inc.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalMedical and Pediatric Oncology
Volume24
Issue number4
DOIs
StatePublished - Apr 1995

Keywords

  • CNS tumor
  • Sagramostim
  • cyclophosphamide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms'. Together they form a unique fingerprint.

Cite this